Purpose: We recently demonstrated the efficacy of
tadalafil treatment for
fetal growth restriction (FGR). This study aimed to evaluate the utility of serum placental
growth factor (PlGF) level for predicting the efficacy of
tadalafil for the treatment of FGR. Materials and methods: The correlations between serum level of PlGF and fetal growth velocity were retrospectively assessed in nine pregnant women receiving
tadalafil for FGR before 30 weeks' gestation. Results: Median gestational age was 26 weeks (range 26-28 weeks), and median deviation of estimated
fetal weight from standard weight was -2.1 standard deviations (SD) (-2.2 to -1.9 SD) at the beginning of
tadalafil treatment. The median serum PlGF level was 227 pg/ml (40.2-427.0 pg/ml) before
tadalafil treatment and 278 pg/ml (66.2-729.5 pg/ml) more than 2 weeks after initiation of
tadalafil treatment (median gestational week at measurement of PlGF
after treatment, 33 weeks [28-33 weeks]). The median fetal growth velocity from enrollment to birth was 17.5 g/day (12.1-20.3 g/day). Maternal serum PlGF levels were increased after
tadalafil treatment in all nine cases (median increase in PlGF, 73.1 pg/ml [26.0-281.5 pg/ml]). Notably, maternal serum PlGF level before
tadalafil treatment significantly correlated with fetal growth velocity (R2 = 0.63, p < .01). Conclusions:
Tadalafil treatment may increase maternal serum PlGF levels. Our results suggest that maternal serum PlGF levels can be used as a predictor of the efficacy of
tadalafil treatment for FGR.